How to Reduce Hair Loss on Mounjaro — What the Evidence Actually Shows

What the SURMOUNT trials recorded, and why the mechanism matters

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, hair loss was among the side effects reported by a meaningful proportion of participants on tirzepatide, particularly at higher doses. The rate tracked with the degree of weight reduction: the more rapidly bodyweight fell, the more frequently participants reported shedding. That pattern points directly to telogen effluvium, a well-documented physiological stress response in which the body, sensing significant caloric deficit, shifts hair follicles from their growth phase into a resting phase prematurely. Three to four months later, those follicles shed simultaneously. The hair loss arrives well after the trigger; that timing catches many people off guard.

A common assumption is that Mounjaro is somehow attacking the follicle itself. It isn't. The mechanism behind Mounjaro-related hair loss is metabolic, not pharmacological in that direct sense, follicles respond to the body's energy state, not to tirzepatide molecules. That distinction matters practically: addressing the metabolic trigger is where most evidence-based strategies sit. The NHS tirzepatide medicines page lists hair loss among the less common side effects and notes it typically resolves without intervention.

One point worth naming and letting go: some people stop treatment the moment they notice shedding, believing it will only worsen. In most cases, hair loss peaks and then naturally decelerates as the body adapts, discontinuing treatment abruptly rarely helps the hair and removes the clinical benefit you've worked to achieve.

Protein, micronutrients and the practical steps that have the strongest support

Because telogen effluvium is driven by nutritional stress, the most evidence-consistent approach to limiting hair loss on Mounjaro centres on diet quality rather than topical treatments or supplements. Tirzepatide substantially reduces appetite, which makes it genuinely difficult to meet protein targets. Yet protein is the raw material for keratin, and inadequate intake accelerates follicle dormancy during caloric restriction. Most nutritional guidance for adults during active weight loss suggests aiming for roughly 1.2–1.6 g of protein per kilogram of bodyweight per day, your prescriber or a registered dietitian can help you set a figure appropriate for you personally.

Beyond protein, iron, zinc, biotin and vitamin D deficiencies have each been associated with increased hair shedding in the medical literature, and weight-loss diets can narrow dietary variety. A blood panel arranged through your GP can identify any gaps. Correcting a genuine deficiency often has a more meaningful effect on shedding than adding a supplement that isn't addressing a real shortfall. Some people also find that Mounjaro watery diarrhea compounds the challenge, since persistent GI symptoms can further reduce both fluid and nutrient absorption, adding to the pressure on follicles. For broader context on managing Mounjaro's side-effect profile, our clinical overview covers the full picture.

Strength and resistance training during treatment also helps preserve lean muscle mass, which in turn supports a more stable metabolic environment for hair follicles. This is an area where the evidence is indirect but consistent enough that most specialist services now recommend it alongside dietary support.

Steps specific to women, and why hormonal factors deserve a separate conversation

Hair loss during Mounjaro treatment can affect anyone, but the experience is frequently more distressing for women, partly because female-pattern hair changes tend to be more visible and partly because hormonal factors can compound the telogen effluvium picture. Thyroid function, perimenopausal hormone shifts and iron-deficiency anaemia are all more prevalent in women and can independently drive shedding, meaning what looks like a straightforward treatment side effect may have more than one contributor running simultaneously.

Women on oral contraceptives should also be aware that tirzepatide slows gastric emptying, which can transiently reduce absorption of oral medications including the pill; NHS guidance recommends adding a non-oral contraceptive method for the first four weeks of treatment and for four weeks after any dose increase. This is worth discussing with your prescriber rather than assuming your current method is unaffected. Female-specific guidance on stopping hair loss with Mounjaro covers these overlapping factors in more detail. Separately, if you are considering approaches used across the tirzepatide class more broadly, the principles are essentially the same, the medicine is the same compound.

When hair loss needs medical attention, and how to report concerns

Most tirzepatide-related shedding is self-limiting. That said, there are presentations where hair loss warrants prompt medical review rather than a watchful approach. Speak to a prescriber or your GP without delay if: shedding is severe and sudden rather than gradual; you notice bald patches or scalp inflammation rather than diffuse thinning; hair loss is accompanied by other new symptoms such as fatigue, cold intolerance or joint pain (which could point to a thyroid or autoimmune process); or if shedding shows no signs of slowing after 6–9 months on a stable dose.

Side effects from licensed medicines, including hair loss, can be reported directly to the MHRA via the Yellow Card reporting scheme. Doing so contributes to the post-market safety database for tirzepatide, which carries a Black Triangle (▼) designation indicating ongoing MHRA monitoring. You do not need a clinician to submit a Yellow Card report, patients can file one directly. If you have questions about your treatment or want to discuss practical prevention strategies before you begin, our prescribers address these during every consultation. Start your free consultation and a GPhC-registered clinician will review your case the same day.